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Accepted 3 July 2017; Published online 8 July 2017AbstractPragmatic trials may deliver real-world evidence on the added value of new medications compared with usual care and inform decision
making earlier in development. This fifth paper in a series on pragmatic trials in the Journal discusses usual care as a comparator and the
allocation of treatment strategies. The allocation and implementation of treatment strategies should resemble clinical practice as closely as
possible. Randomization at the level of the site, as opposed to at the individual level, may be preferred. Data analysis according to the
intention-to-treat principle is recommended, and crossover between treatment arms and strong treatment preferences may be accounted
for in the study design in specific situations. Although usual care is the comparator of choice, this may differ substantially between centers
and countries complicating comparator choice. Using clinical guidelines to define usual care can be helpful in standardizing comparator
treatments; however, this may decrease the applicability of the results to real-life settings. Conversely, using multiple usual-care treatment
arms will increase the complexity of the study. The specific objectives of the trial and design choices should be discussed with all stake-
holders to realize the full potential of the pragmatic trial.  2017 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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New drugs are typically examined for their efficacy and
safety in randomized clinical trials (RCTs), under strictly
controlled conditions in highly selected patient groups. If
the results obtained by these explanatory trials do not reflect
treatment effects in patients seen in day-to-day clinical prac-
tice, they cannot adequately guide physicians’ treatment de-
cisions [1,2]. Pragmatic trials can deliver real-worldConflict of interest: M.G.P.Z., P.M.J.W., G.J.M.W.v.T., A.C., M.J.C.E.,
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licenses/by-nc-nd/4.0/).evidence on the value of new treatments comparedwith usual
care [1,3].When executed well, pragmatic trials maintain the
strength of an RCT but also generate results that are appli-
cable to routine clinical practice.
Treatment-related study procedures in pragmatic trials
should not change routine clinical practice. Decisions on
drug dosage, co-interventions, and the management of
adverse effects are therefore left to the physician [1].
Placebos and other methods of blinding patients and physi-
cians for the assigned treatment group are generally not used
in pragmatic trials, as knowledge of the treatment status, and
expectations or behavior changes associatedwith that knowl-
edge are part of the treatment effect in real life. In addition,
any measures taken to promote treatment adherence should
reflect routine clinical practice [4]. The focus therefore is
on comparing the effectiveness of treatment strategies rather
than on the efficacy of single compounds [5].
The Pragmatic Explanatory Continuum Indicator Sum-
mary (PRECIS) tool [6] has been developed and revisedcess article under the CC BY-NC-ND license (http://creativecommons.org/
Box 1 Series on pragmatic trials
Pragmatic trials aim to generate real-world evi-
dence on the (relative) effects of treatments, general-
izable to routine practice. In this series, we will
discuss options and choices for pragmatic trial
design, operational consequences, and the interpreta-
tion of results.
1. Introduction
2. Setting, sites, and investigator selection
3. Patient selection challenges and consequences
4. Informed consent
5. Usual care and real life comparators
6. Outcome measures in the real world
7. Safety, quality and monitoring
8. Data collection and management
93Clinical Epidemiology 90 (2017) 92e98What is new?
Key findings
 Pragmatic trials can deliver real-world evidence on
the added value of new medications to support
clinical decision making earlier in drug
development.
 The research question determines whether new
treatments are started or an existing treatment is
continued, whether treatment switches between
arms are allowed, and whether a superiority or
noninferiority design is more appropriate.
 Usual care is the comparator of choice for prag-
matic trials, but implementation may be difficult
if usual care differs between centers or countries.
What this adds to what was known?
 In this paper, we discuss the operational and meth-
odological challenges in pragmatic trials related to
defining and comparing treatment strategies and
the choice of suitable comparator(s).
What is the implication and what should change
now?
 In pragmatic trials, all elements of trial conduct
should interfere with or change routine clinical
practice as little as possible.
 Treatment strategies under study should resemble
routine care as closely as possible, including
dosing, comedication, and the supply and reim-
bursement of drugs.
M.G.P. Zuidgeest et al. / Journal of(PRECIS-2) [4] to support investigators in making trial
design choices that are in line with the purpose of their
study. Topics include for instance eligibility criteria, patient
recruitment, and organizational considerations. Our series
of eight articles in this journal (see Box 1) aims to extend
this work by describing potential challenges and solutions
in conducting trials that address the relative effectiveness
of drugs in real-world clinical practice, specifically before
or shortly after a drug is licensed and launched on the
market.
In this paper, we discuss the choice of the usual-care
comparator, which is a central issue in pragmatic relative
effectiveness research but is largely missing from
PRECIS-2 [7]. We describe the operational and methodo-
logical challenges in pragmatic trials pertaining to defining
and comparing treatment strategies and the choice of suit-
able usual-care comparator(s) for drug evaluation [8].
These factors affect the applicability of the results and their
acceptance by different stakeholders [9].2. Research questions and comparisons
A treatment in routine clinical practice can be compared
with usual care in several ways in a pragmatic trial, depend-
ing on the question that is addressed. For example, patients
with well-controlled type-2 diabetes using oral antidiabetic
medication can be randomly assigned to either switching to
a new treatment or to continuing their current treatment.
This would address a first question of whether the new
treatment has advantages over usual care with regard to
adverse effects, costs, convenience, or the control of body
weight while maintaining glycemic control. If the new
treatment is expected to have certain advantages but equal
effectiveness, a noninferiority design may be appropriate
[10]. Alternatively, for patients whose blood sugar is not
well controlled, a second question arises, namely whether
blood sugar control could be improved with a new treat-
ment. In this case, either the new treatment could be
compared to continuation of the current treatment, or
different new treatments can be compared. Third, newly
diagnosed patients may be randomized to a treatment
recommended by current guidelines or a new treatment
strategy. Depending on the research question and character-
istics of treatments, noninferiority or superiority designs
may be appropriate in the latter two situations.
It is essential to define the question a pragmatic trial is
supposed to answer. The question will inform the design
choices and determine how investigators deal with switches
(crossovers) to the treatment in the other trial arm (see Sec-
tion 4.5 and Table 1). The first question mentioned previ-
ously may be the easiest to address from an operational
perspective because eligible patients can readily be identi-
fied among a pool of patients with type-2 diabetes; but trial
results will not be applicable to patients newly diagnosed
Table 1. Questions, comparisons, and treatment switches that should be allowed in pragmatic trials
Question Comparisons Switches
Should the new treatment be approved
and made available?
A health system with access to the new
treatment and UC (arm 1) is compared to a
health system with access to UC only
(arm 2).
Switches from new treatment to UC are
allowed in arm 1. No switches are allowed
in arm 2.
Which of two approved treatment should
be the first-line treatment of choice?
A health system with access to two
treatments. In arm 1, therapy is initiated
with the first treatment, in arm 2 with the
second treatment.
Switches in both directions are allowed.
Should a new treatment replace an old
treatment on the list of approved
treatments?
A health system using only the new treatment
is compared to a system where only the old
treatment is available.
No switches should be allowed.
Should the new treatment be used as
first-line or second-line treatment, or
not at all?
A health system using the new treatment as
first-line and UC as second-line treatment
(arm 1); a health system with UC and the
new treatment as second-line treatment
(arm 2); a health system with access to
usual care only (arm 3).
Switches are part of the intervention in arm 1
and arm 2, but not allowed in arm 3.
Abbreviation: UC, usual care.
Adapted from Torrance et al. [11].
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inferiority design is that generally more patients are needed
for such a design [10].3. Choice of usual-care comparators
The choice of appropriate comparators is a central issue
in pragmatic trials. The European Network for Health
Technology Assessment (EUnetHTA) defines a comparator
in a relative effectiveness assessment as ‘‘[.] a health care
intervention or other technology with which a pharmaceu-
tical is compared in order to establish if it has an added
therapeutic benefit. Such comparator could be another phar-
maceutical, but also a medical device, a procedure or psy-
chological approach, radiotherapy, physiotherapy, surgery
or, if appropriate, providing advice, for example advice
on diet or smoking, a combination of health care interven-
tions carried out simultaneously or in sequence, or ‘watch-
ful waiting’ (no intervention)’’ [12].
Usual care is the comparator of choice in pragmatic tri-
als [4,6]. Although conceptually straightforward, choosing
an adequate comparator in pragmatic trials can be chal-
lenging [13,14], for example, when several usual-care op-
tions exist or when guidelines differ from usual care. The
definition of usual care in multicenter trials may be compli-
cated by variations in usual care across centers, regions, or
countries [15]. In these situations, the applicability to a cen-
ter or region has to be weighed against wider generaliz-
ability of results to a country or countries. In trials with a
long duration, usual care may change during the conduct
of a trial, for example, due to changes in reimbursement
or a new medication that becomes available on the market.
In this situation, changes in usual care in newly recruited
patients, or switches to a new usual care regimen in
enrolled patients, may be appropriate to continuously
reflect routine clinical practice.3.1. Fixed or flexible choice of usual care
In determining usual care, there may not always be a
single, optimal comparator. Rather, several appropriate
choices may exist [16]. Different usual-care options may
be included as separate arms, but this will increase
complexity and costs, and physicians may object to (some
of) the options [15,17]. Alternatively, different usual-care
options may be combined into one comparator arm with
the choice of treatment left to the physician. Although this
approach may follow routine clinical practice most closely,
the results might be applicable to a smaller number of set-
tings with a similar mix of usual-care options. In addition,
the estimates of relative effectiveness compared to a mix of
usual-care options may be more relevant to policymakers
than to clinicians whose primary interest is to find the best
treatment for individual patients. In general, in pragmatic
trials clinical investigators will less likely be faced with a
conflict of duties (strict adherence to study protocol vs. pro-
vision of optimal patient care) [18] than in other trials, for
example, placebo-controlled trials, because pragmatic trials
mimic routine clinical care.3.2. Clinical guidelines and usual care
According to the Declaration of Helsinki, new treatments
must be tested against the best proven intervention or inter-
ventions [19]. Using less-than-optimal comparator treat-
ments in trials of new drugs may disturb equipoise and
raise ethical concerns [17,20]. EUnetHTA has published rec-
ommendations for the choice of comparators for relative
effectiveness research that are relevant for pragmatic trials
(see Table 2) [12]. These recommendations can help identify
comparators that comply with the aim of comparing a new
treatment strategy against usual care while respecting the
ethical principles of providing patients with the best avail-
able care. The recommendations state that the choice should
Table 2. EUnetHTA recommendations for the choice of comparators in relative effectiveness studies
 The comparator should be the reference treatment according to up-to-date high-quality clinical practice guidelines at European or international
level. If no such guidelines exist, evidence is required that the chosen comparator intervention is routinely used in clinical practice.
 Evidence that the intervention is used in routine clinical care could come, in order of preference, from
B National reimbursement lists if available
B Prescription statistics (if appropriate)
B Market surveys
B Discussion with clinical specialists and patient organizations
B Registries
B Validated clinical protocols
B Internet searches, in particular patient and professional web sites
 The choice of comparator should be supported by evidence on its efficacy and safety profile described in published medical literature, and based
on randomized controlled trials, pragmatic trials, or good-quality observational studies.
 Pharmaceuticals have to be optimally dosed or scheduled in line with marketing authorization or high-quality clinical practice guidelines.
 Where patient subpopulations are considered, for example, according to disease severity, lines of treatment, stages of disease, or genetic
characteristics, additional comparators may need to be included.
 The most appropriate comparators should be identified before the assessment begins or in the early phase of an assessment.
Abbreviation: EUnetHTA, European Network for Health Technology Assessment.
Adapted from EUnetHTA methodological guideline for relative effectiveness assessment (REA) of pharmaceuticals [12].
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if no such guidelines exist, evidence that the treatment stra-
tegies are routinely used in clinical practice. Using treatment
guidelines to define usual care can be helpful in standard-
izing comparator treatments; however, this will decrease
the level of pragmatism and may reduce the applicability
of the results to routine clinical practice. The routinely used
treatments can, on the other hand, vary considerably between
countries and settings, depending on the health care system
and availability of resources [21,22]. Some centers will
follow (inter)national treatment guidelines, whereas others
may have developed their own recommendations. The re-
sults of a trial may, therefore, be applicable to a specific
setting (e.g., where guidelines are followed) but may not
be generalizable to others.4. Allocation and implementation of treatment
4.1. Random allocation
The random allocation of patients to treatments aims to
reduce confounding due to differences in prognostic
variables that may be present between treatment arms.
A computer algorithm generates the allocation sequence,
and this sequence is concealed from those enrolling patients
because knowledge of the allocation might influence enroll-
ment and lead to groups that differ in prognostic factors
[23,24]. The randomization process can be challenging
for routine care sites that are unfamiliar with clinical
research [25]. Web-based randomization procedures that
assign patients to groups after assessing eligibility and
recording informed consent are most suitable for pragmatic
trials in routine care settings [25,26].
4.2. Level of randomization
In RCTs, patients are typically individually assigned to
treatment groups. However, in some situations, therandomization of groups or units such as general or
specialist practices or hospitals may be preferable. Such sit-
uations arise, for example, if there is a danger that compo-
nents and effects of the experimental treatment strategy
spill over to the comparator care strategy, thus introducing
bias, or if randomization of patients in a medical setting
changes the routine care process. These situations are more
common in open, pragmatic trials than in explanatory trials,
and the appropriate level of randomization should therefore
be explicitly considered when designing a pragmatic trial
[14]. Disadvantages of cluster trials compared with individ-
ually randomized trials include the need for a larger sample
size, the increased risk of imbalances in prognostic factors
between groups (especially if the number of centers
included is low), and the possibility of postrandomization
selection bias [27,28]. In addition, specific strategies for
informed consent may be needed, and these can be chal-
lenging from a regulatory and ethical perspective [29].4.3. Dealing with treatment preferences
Patients may have a strong preference for a specific treat-
ment based on their expectations of the benefits and their con-
cerns about potential risks, side effects, and their attitude
toward exposure to experimental drugs. The views of patients
may differ from those of other important stakeholders, such
as physicians [30]. Strong patient preferences may influence
participation, affecting generalizability, but could also affect
the validity of a pragmatic, open-label trial if patients ran-
domized to the nonpreferred treatment experience ‘‘resentful
demoralization’’ [31] and consequently show low adherence
to the assigned treatment. Conversely, better adherence to a
preferred treatment may produce results that exaggerate the
effectiveness of the intervention [32]. A study design in
which patients can choose their treatment should be consid-
ered when preferences are expected to affect recruitment or
adherence [33,34]. In so-called comprehensive cohort de-
signs, patients with strong preferences may choose their
96 M.G.P. Zuidgeest et al. / Journal of Clinical Epidemiology 90 (2017) 92e98treatment, whereas other patients are randomly allocated. As
patients with and without strong preferences are included,
generalizability of the randomized part of the study can be
evaluated. However, comparisons between nonrandomized
groups are likely confounded and inclusion of preference
arms can increase the costs as well as the complexity of trial
execution, which should be carefully weighed against the
benefits. In the absence of a preference arm, it may still be
useful to record treatment preferences to be able to assess
their influence on outcomes [34].4.4. Supply of medication
In contrast to day-to-day clinical practice, in clinical tri-
als, the drugs are commonly directly provided to patients
by the investigator. Direct supply of study medication to pa-
tients by the investigator can shorten the time to start of
treatment, and it may increase the proportion of patients
starting treatment and adherence and thus influence gener-
alizability of results to the setting of interest [35]. As prag-
matic trials aim to mimic real-life clinical practice, this
should also be reflected in the way medication is offered
to the patient. The supply of the study medication should
therefore ideally be left to the health care provider rather
than specified in the trial protocol [1,3,36]. Of note, if com-
munity pharmacies provide experimental medicines that are
not approved, training of pharmacists in good clinical prac-
tice will be required [35].
Differences in copayment for patients between trial and
daily practice also need to be considered [37]. Such differ-
ences may affect participation and reduce generalizability
of results. In addition, if the experimental medicines are
free or fully reimbursed (which is often mandatory) but
the comparator is not, then switching of treatments may in-
crease above what could be expected in daily practice and
distort results. In this situation, full reimbursement should
be considered for both arms because only providing full
reimbursement for the experimental arm could give this
treatment an advantage over usual care within the trial envi-
ronment that will most likely not pertain in real life.4.5. Dealing with switches
How to deal with patients wishing to switch to the other
treatment arm (crossovers) depends on the research ques-
tion asked [11,38] (see Box 1). Crossing over to the
usual-care arm should be possible if the primary question
is whether the new drug should be added to the list of
approved treatments. Crossing over to the new treatment
should, however, not be allowed because such switches
would not be in line with current routine clinical practice
(where the new drug is not available) [11]. If all treatments
are already available in clinical practice, switches in both
directions may be appropriate, as described in Table 1.
Switches should be recorded if this is possible without
interfering with routine care.4.6. Dose and comedication
Dose of medication and comedication should be in line
with routine clinical practice and left to the discretion of the
treating physician who will optimize treatment in individ-
ual patients in a pragmatic trial. However, physicians may
find this challenging with new medications where there is
no or limited experience regarding dose adjustments and
comedications, for example, prelaunch. Especially with
a real-life population, it is more likely that subgroups
(e.g., based on age or severity of the disease) require
different doses of a drug [39]. In this situation, clinicians
will need guidance based on the best available evidence,
which may come from smaller (phase II) trials.4.7. Data analysis
In any pragmatic trial, the data should be analyzed ac-
cording to the intention-to-treat principle which stipulates
that comparisons are according to the originally random-
ized groups. Other analyses, including per-protocol ana-
lyses or analyses censoring follow-up at the time of
switching, will tend to be biased [40]. Patients who switch
and those who use comedication will often differ from
those who do not with respect to prognostic factors [38].
The focus of the analysis should be the effectiveness of
the treatment strategies achieved in a real-life situation
and thus include patients who switch, use comedication,
or have suboptimal adherence.5. Discussion
A well-specified research question should guide the
operational and methodological design choices of prag-
matic trials that aim to assess the added value of a
new treatment strategy relative to a treatment strategy
used in real-world clinical practice. The treatment-
related study procedures, including the allocation and
definition of the treatment strategy, must resemble routine
clinical practice as closely as possible. Cluster randomi-
zation at the level of the site, as opposed to at the indi-
vidual level, may be preferred. Data analysis according to
the intention-to-treat principle is recommended to ensure
valid comparisons, and crossover between treatment arms
and strong treatment preferences may be accounted for in
the design of the study in specific situations. Although
usual care is the comparator of choice in pragmatic trials,
operationalization of this design feature may be difficult,
among others because usual care may differ between cen-
ters and countries.
Groups such as the Consolidated Standards of Report-
ing Trials (CONSORT) and Pragmatic Trials in Health-
care state that the acceptation and reporting of
pragmatic randomized trials should be improved. Their
statement emphasizes the necessity of a detailed descrip-
tion of the question that is addressed by a trial and the
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criteria, and deviations from usual-care procedures in
the research sites for the trial [41]. To make correct in-
ferences of generalizability of trial findings to different
settings, trial reporting should preferably also encompass
detailed information on the treatment strategies compared
(including real-life dosing, comedication, switching pat-
terns and reasons, patient follow-up, supply of medica-
tion). However, collection of this information on
administration of treatment and management of patients
should not change routine clinical practice.
Pragmatic trials have the potential to provide real-
world evidence on relative effectiveness early in the eval-
uation process to support clinicians in their treatment
choices. Although the term ‘‘pragmatic trial’’ was coined
in 1967 [1], pragmatic trials are a relatively recent addi-
tion to the family of methods used in clinical research,
with the number of published pragmatic trials increasing
steeply in recent years. Therefore, their potential contri-
bution to the drug evaluation process and market autho-
rization should be further emphasized and discussed,
for instance regarding reducing the delay in reimburse-
ment. In the meantime, trialists should engage in a dis-
cussion with all stakeholders on the goals of the trial,
the specific question to be answered, and preferences
and requirements for design choices to realize the full
potential of pragmatic trials [42].Acknowledgments
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